Imagine two people with similar levels of peanut-specific antibodies, yet one can enjoy a handful of peanuts without issue, while the other faces a life-threatening reaction. This baffling disparity has long puzzled scientists—until now. A groundbreaking study published in Cell Host & Microbe on March 3, 2026, reveals that the secret may lie in the bacteria residing in our mouths and guts. But here’s where it gets even more fascinating: these microbes might hold the key to predicting and even reducing severe peanut allergy reactions.
Led by researchers at McMaster University, the study sheds light on how gut bacteria break down components of allergenic foods, potentially influencing how our bodies react to peanuts. Peanut allergies are among the most prevalent food allergies in Canada, affecting one in two households. And this is the part most people miss: understanding this microbial connection could pave the way for revolutionary treatments and preventive measures.
“Peanut allergies can trigger severe reactions, from difficulty breathing to anaphylaxis, yet some individuals tolerate small amounts without issue,” explains Liam Rondeau, a postdoctoral fellow at McMaster’s Farncombe Family Digestive Health Research Institute. “We discovered that certain mouth microbes play a critical role in this phenomenon.”
Researchers analyzed saliva and upper gut samples from healthy volunteers, identifying specific bacterial species capable of breaking down major peanut allergens. One standout was Rothia, a bacterium that reduces the ability of peanut proteins to bind with antibodies—the very process that triggers allergic reactions. But here’s the controversial part: could manipulating these bacteria offer a new way to manage allergies? The study also found that individuals with peanut allergies who had higher levels of allergen-degrading bacteria could tolerate larger amounts of peanuts before reacting.
“Our findings highlight a previously unknown link between the oral and gut microbiome and food allergies,” says co-senior author Alberto Caminero Fenandez. “This opens up exciting possibilities for predicting and treating allergies through microbial or probiotic therapies.”
The team validated their findings in a dataset of 120 children, confirming that Rothia was more abundant in those with higher peanut tolerance. Pre-clinical experiments further showed that Rothia reduced allergen levels in the bloodstream, suppressed immune cell activation, and triggered milder reactions. But here’s the question that sparks debate: If these bacteria are so influential, why aren’t they already part of allergy treatment protocols?
Peanut allergies are the most common food allergy among Canadian children, with strict avoidance as the only recommended management strategy. Yet, accidental exposures are frequent, and peanut allergies remain the leading cause of allergy-related deaths in children. This research offers hope for new approaches, such as microbial therapies or improved oral immunotherapy.
Conducted by a multicentre team from McMaster University, Spain, and the United States, the study was funded by organizations including the New Frontiers in Research Fund, Nutricia Research Foundation, and the Canadian Institutes of Health Research. Now, we ask you: Could this microbial breakthrough redefine how we approach food allergies? Share your thoughts in the comments—let’s spark a conversation!
